(68)Ga-PSMA PET/CT impact on prostate cancer management

Aim: To assess the impact of (68)Ga-Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography/ Computed Tomography (PET/CT) on management of prostate cancer in patients with biochemical recurrence (BCR). Methods: Documented management plans were retrospectively reviewed before and after (68)Ga-PSMA PET/CT in 100 patients with BCR and change in plans recorded. Results: Management changed after (68)Ga-PSMA PET/CT in 39 patients (39%). These occurred in 23/68 (33.8%) of patients with radical prostatectomy (RP) and 16/32 (50%) of patients previously treated with radical radiotherapy. Positive scan (P < 0.001) and higher Prostate Specific Antigen (PSA) (P = 0.024) were associated with management changes. No significant association with management change was found with Gleason grade, stage, presence of metastatic disease, PSA velocity or doubling time. Conclusion:(68)Ga-PSMA PET/CT altered management in 39% of patients with BCR, and occurred more often in patients with radical radiotherapy treatment, a positive (68)Ga-PSMA scan and higher PSA level.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017 Jul 26 [Epub ahead of print]

Asim Afaq, Suliman Alahmed, Shih-Hsin Chen, Thabo Lengana, Athar Haroon, Heather Payne, Hashim Ahmed, Shonit Punwani, Mike Sathekge, Jamshed Bomanji

Institute of Nuclear Medicine, University College London, United Kingdom., King Khalid University Hospital, Saudi Arabia., Chang Gung Memorial Hospital, Taiwan., Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, South Africa., Department of Nuclear Medicine, St Bartholemew's Hospital, Barts Health NHS Trust., United Kingdom., Department of Oncology, University College London, United Kingdom., Department of Urology, University College London, United Kingdom., Centre for Medical Imaging, University College London, United Kingdom.